{"id":186765,"date":"2018-02-14T09:56:01","date_gmt":"2018-02-14T09:56:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=186765"},"modified":"2018-02-14T09:56:01","modified_gmt":"2018-02-14T09:56:01","slug":"human-microbiome-drugs-market-2018-current-and-future-plans","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/human-microbiome-drugs-market-2018-current-and-future-plans_186765.html","title":{"rendered":"Human Microbiome Drugs Market 2018 – Current and Future Plans"},"content":{"rendered":"
Pune, India, 14th February 2018: WiseGuyReports announced addition of new report, titled \u201cHuman Microbiome-based Drugs and Diagnostics: Global Markets\u201d.\t<\/div>\n

Report Scope:<\/strong><\/p>\n

The scope of the study includes the major microbiome-based drugs<\/a><\/strong> and diagnostics that are likely to be commercialized within the next eight years. Each product within each market is analyzed to determine its market status, market potential during the time period of 2018 to 2024. Microbiome intellectual property, investments and collaborations are discussed.<\/p>\n

 <\/p>\n

Influencing factors, industry structure, challenges facing the industry and patent status are discussed. BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. We profile 25+ companies participating in this rapidly developing and evolving sector.<\/p>\n

 <\/p>\n

GET SAMPLE REPORT @ https:\/\/www.wiseguyreports.com\/reports\/2820056-human-microbiome-based-drugs-and-diagnostics-global-markets<\/a>          <\/em><\/strong><\/p>\n

 <\/p>\n

Report Includes:<\/strong><\/p>\n

– An overview of the global markets for human microbiome-based drugs and diagnostics.<\/p>\n

– Analyses of global market trends, with estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2024.<\/p>\n

– Coverage of areas and applications where these technologies are applicable, such as cancer, diabetes, allergic disorders, irritable bowel disorders, celiac disease, and other G.I. disorders.<\/p>\n

– An in-depth look at macro-level trends affecting this sector.<\/p>\n

– Market intelligence on the technologies and platforms currently being deployed to develop these drugs and diagnostics.<\/p>\n

– Specific emphasis on the products in development for various diseases, including the specific forecasts for these products by disease and geography.<\/p>\n

– A look at the current level of investments in the sector, intellectual property development, and future of this sector.<\/p>\n

 <\/p>\n

Key Players<\/span><\/strong><\/p>\n

4D PHARMA<\/p>\n

AOBIOME LLC<\/p>\n

AVIDBIOTICS INC.<\/p>\n

AXIAL BIOTHERAPEUTICS<\/p>\n

C3 JIAN INC.<\/p>\n

CAELUS HEALTH<\/p>\n

DA VOLTERRA<\/p>\n

ELIGO BIOSCIENCES<\/p>\n

ENTEROME BIOSCIENCES<\/p>\n

EVELO BIOSCIENCES<\/p>\n

EVOLVE BIOSYSTEMS<\/p>\n

METABIOMICS<\/p>\n

MICROBIOME THERAPEUTICS<\/p>\n

ORIGIN SCIENCES LTD.<\/p>\n

OSEL INC.<\/p>\n

OXTHERA<\/p>\n

REBIOTIX INC.<\/p>\n

RITTER PHARMACEUTICALS<\/p>\n

SECOND GENOME<\/p>\n

SERES THERAPEUTICS<\/p>\n

SYMBERIX<\/p>\n

SYNLOGIC BIOTICS<\/p>\n

SYNTHETIC BIOLOGICS<\/p>\n

UBIOME INC.<\/p>\n

VEDANTA BIOSCIENCES<\/p>\n

VITHERA PHARMACEUTICALS<\/p>\n

 <\/p>\n

Table of Content: Key Points<\/span><\/strong><\/p>\n

Chapter 1 Introduction<\/p>\n

Study Goals and Objectives<\/p>\n

Reasons for Doing This Study<\/p>\n

Intended Audience<\/p>\n

Scope of Report<\/p>\n

Information Sources<\/p>\n

Methodology<\/p>\n

Geographic Breakdown<\/p>\n

Analyst’s Credentials<\/p>\n

Chapter 2 Summary and Highlights<\/p>\n

Chapter 3 Microbiome Overview<\/p>\n

Scientific Background<\/p>\n

Human Microbiome in Health and Disease<\/p>\n

Advances in Microbiome Research<\/p>\n

Focus Areas for Microbiome-Based Drugs and Diagnostics<\/p>\n

Microbiome-Based Drugs: Product Development Strategies<\/p>\n

Current Challenges in Microbiome Drug Development<\/p>\n

Human Microbiome Project<\/p>\n

MetaHIT Consortium<\/p>\n

Public Sector Initiatives in Microbiome Research<\/p>\n

Key Goals of the Human Microbiome Project<\/p>\n

Key Achievements of the Human Microbiome Project<\/p>\n

Key Goals of MetaHIT Initiative<\/p>\n

Chapter 4 Human Microbiome-Based Drugs Market<\/p>\n

Cancer<\/p>\n

Obesity<\/p>\n

Type 2 Diabetes<\/p>\n

Ulcerative Colitis and Crohn’s Disease<\/p>\n

…Continued                             <\/strong><\/p>\n

 <\/strong><\/p>\n

ACCESS REPORT @ https:\/\/www.wiseguyreports.com\/reports\/2820056-human-microbiome-based-drugs-and-diagnostics-global-markets<\/a>        <\/em><\/strong><\/p>\n

          <\/strong><\/p>\n

Get in touch:                                                          <\/strong><\/p>\n

LinkedIn: <\/strong>www.linkedin.com\/company\/4828928<\/strong><\/a><\/p>\n

Twitter: <\/strong>https:\/\/twitter.com\/WiseGuyReports<\/strong><\/a>                                                                   <\/strong><\/p>\n

Facebook: <\/strong>https:\/\/www.facebook.com\/Wiseguyreports-1009007869213183\/?fref=ts<\/strong>    <\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> sales@wiseguyreports.com
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Pune, India, 14th February 2018: WiseGuyReports announced addition of new report, titled \u201cHuman Microbiome-based Drugs and Diagnostics: Global Markets\u201d. Report Scope: The scope of the study includes the major microbiome-based drugs and diagnostics that are likely to be commercialized within … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-186765","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/186765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=186765"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/186765\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=186765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=186765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=186765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}